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Challenging "privileged" stereotypes - leukemic blasts and the central nervous system 
Dr Christina Halsey, Institute of Cancer Sciences, College of MVLS, University of Glasgow 
The successful cure of over 90% of children with acute lymphoblastic leukaemia (ALL) is one of the 
most impressive achievements of the last 50 years in haematology. However, challenges remain. One 
particularly problematic area is how best to prevent and/or treat leukaemic relapse in the central 
nervous system (CNS). Early studies established that CNS-directed therapy is essential for cure. 
Accordingly, all modern ALL treatment protocols include large amounts of CNS-directed 
chemotherapy irrespective of the presence or absence of detectable CNS disease at presentation. 
Although reasonably effective, this therapy can cause significant acute and chronic neurotoxicity and 
relapsed disease can be highly refractory to currently available drugs. It is clear that identification of 
the molecular determinants of CNS involvement will aid understanding of leukaemia cell biology, allow 
prognostic models for CNS disease to be developed, and is an essential pre-requisite for design of 
novel therapeutic approaches for CNS disease1.  
Development of CNS leukaemia involves both initial trafficking from the bone marrow to the CNS and 
survival within this compartment. The CNS is traditionally thought of as an immune-privileged site 
with specialised barriers to prevent unselected entry of immune cells2. Several possible routes for 
entry of leukaemic cells across these barriers can be postulated (figure 1).  
 
Figure 1. Schematic representation of potential trafficking routes of leukaemic blasts into the central 
nervous system. Potential sites of entry/exit are labelled A to E. There is experimental and clinical 
evidence for transit across the choroid plexus (A), meningeal vessels (B) and emissary veins (C). 
Leukaemic cells reside within the meninges and pass into the Virchow-Robin spaces surrounding the 
invaginating vessels. Although theoretically possible, there is currently little or no experimental 
support for transit across the blood-brain barrier (BBB) (D) or the dural lymphatics (E).  
 Importantly, histological analysis shows leukaemic cells reside within the leptomeninges, bathed in 
cerebrospinal fluid (CSF). Only rarely, and late in the disease course, is there any evidence of invasion 
into the brain parenchyma, via local breaches of the pial membrane within the leptomeninges3. This 
effectively rules out the blood-brain barrier as the primary site of leukaemia entry, and use of in vitro 
BBB models to model leukaemic trafficking to the CNS should be avoided.  
What about evidence for trafficking across the blood-CSF barrier (BCSFB)? Until now evidence had to 
be gleaned from static histology images showing leukaemic cells residing within the choroid plexus in 
xenograft models and also in the walls of the meningeal veins4. Current knowledge of the mechanisms 
of BCSFB transit is extremely limited. In vivo modelling requiring sampling of CSF is technically difficult 
and often requires use of large animals such as pigs. Early models of the choroid plexus, using rat and 
porcine choroid plexus epithelial cells provided proof of principle that barrier properties such as tight 
junction formation could be replicated in vitro, but require large numbers of animals to harvest tissue 
and have limited applicability to human disease.   
In this issue, März et al report a new in vitro model of the human Blood-CSF barrier and its use to 
investigate transit of B and T cell ALL into the CNS. The authors should be congratulated on developing 
this model, using human choroid plexus papilloma-derived cells. These cells have been extensively 
evaluated for the expression of choroid plexus specific proteins (i.e. tight junction proteins, specific 
transporter proteins), and morphological characteristics, indicating their similarity to choroid plexus 
epithelium. Use of this model should allow mechanistic insights into physiological and pathological 
cellular transit across this important barrier. Using transmission electron microscopy, the authors 
show evidence for transcellular migration of leukaemic cells across this barrier in vitro.  
 
Interestingly, a recent publication from the Sipkins’ laboratory in Nature5 provides compelling 
evidence for an alternative and novel route of non-haematogenous entry for ALL cells to the 
leptomeninges. Using a xenograft model they provide histological evidence that leukaemic cell lines 
and primary cells, track along the outside of emissary vessels that bridge between the calvarial and 
vertebral bone marrow and the dural venous system. This system hijacks pathways used for neural 
progenitors early during neural development and the authors show data suggesting this is dependent 
upon α6 integrin receptor expression on ALL cells and laminin on the abluminal surface of the veins. 
It is noteworthy that intravital fluorescent microscopy was unable to visualise passage of cells across 
the leptomeningeal vessels in this model, although this could be explained by the imaging windows 
used or the experimental set-up. Interestingly, laminin, the ligand for α6 integrin, is also expressed on 
the BCSFB and meninges, so use of both routes remains possible, and there might be important 
differences between mouse models (with very heavy calvarial bone marrow involvement) and human 
patients. 
Both publications also investigate the role of the chemokine CXCL12 in trafficking to the CNS and show 
a modest increase in migration using in vitro modelling. It appears that a variety of chemokines provide 
attractant stimuli for leukemic cells to enter the CNS but that chemokine receptors on leukaemic cells 
do not orchestrate selective entry of cells to this compartment. Most notably there is no current 
experimental evidence for subclonal selection of “CNS-tropic” cells bearing specific receptors, 
suggesting the ability to enter the CNS is a universal property of leukaemic cells4. 
So, these recent publications bring us closer to understanding how cells physically enter the CNS, but 
that is of course only part of the story. Indeed, several lines of evidence support the hypothesis that 
trafficking to the CNS has already occurred at the time a patient presents with leukaemia. This suggests 
that the risk of CNS relapse is determined by the ability of blasts to adapt to the CNS niche and survive 
in this environment, rather than their ability to enter it in the first place. Successful adaptation permits 
cells to evade both systemic chemotherapy and normal immune surveillance. Thus, strategies to block 
leukaemic cell entry may be the equivalent of “locking the stable door after the horse has bolted”.  
Of course, accurate in vitro models of the BCSFB and mechanisms of cellular trafficking into the CNS 
compartment are useful for fields outside ALL biology. CSF plays a central role in CNS homeostasis. 
Elucidating  the mechanisms by which substances, microorganisms and cells cross this barrier is very 
important for understanding disorders of neurodevelopment, neurotoxicology and 
neuropharmacology, as well as many acute and chronic neurological disorders such as bacterial and 
viral meningitis, multiple sclerosis and solid tumour infiltration2. Thus, the model presented by März 
et al provides a useful tool for researchers across a wide range of disciplines.  
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